For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
The group eyes a broader use than Immunocore’s Kimmtrak.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
It’s back to school for biotech, with a packed conference schedule.
